<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>医疗设备制造商 Coloplast A/S (COLO-B.CO) 周二报告其第二季度亏损，相比于去年同期的盈利，主要受到与 Kerecis 相关的大额减值损失的影响，尽管收入有所增长。此外，该公司重申了 2026 财年的展望。</p>
<p>在哥本哈根，股价上涨约 0.37%，交易价格为 402.00 丹麦克朗。</p>
<p>在第二季度，公司录得净亏损 9.71 亿丹麦克朗，而去年同期的盈利为 9.12 亿丹麦克朗。每股亏损为 4.31 丹麦克朗，而去年同期的盈利为 4.05 丹麦克朗。</p>
<p>最新的业绩主要受到与 Kerecis 相关的 30.3 亿丹麦克朗的特殊减值损失的影响，因为预计皮肤替代品的市场复苏速度较慢。</p>
<p>调整后的每股收益为 6.16 丹麦克朗，而去年同期为 4.34 丹麦克朗。</p>
<p>在特殊项目之前的营业利润或 EBIT 较去年下降 4%，至 18.2 亿丹麦克朗。调整后的 EBITDA 下降 3%，至 21.7 亿丹麦克朗。</p>
<p>调整后的 EBIT 利润率为 26%，而去年为 27%。</p>
<p>Coloplast 在第二季度实现了 6% 的有机增长和 6% 的 EBIT 增长（以固定汇率计算）。慢性护理和介入性泌尿学表现强劲，而伤口与组织修复的季度表现则面临挑战。</p>
<p>尽管受到货币的 4 个百分点的负面影响，收入仍增长 2%，从去年的 69.3 亿丹麦克朗增至 70.8 亿丹麦克朗。有机增长为 6%。</p>
<p>此外，公司表示将支付每股 5.00 丹麦克朗的半年期中期股息，总股息支付为 11.3 亿丹麦克朗。</p>
<p>展望 2026 财年，Coloplast 表示预计收入增长约为 3%，货币的负面影响为 2% 至 3 个百分点，有机收入增长为 5% 至 6%，调整后的 EBIT 在固定汇率下增长约 5%。</p>
<p>年度业绩将包括约 31 亿丹麦克朗的特殊项目，反映 Kerecis 的减值损失。</p>
<p>有关更多盈利新闻、盈利日历和股票盈利信息，请访问 rttnews.com。</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

天弘国证生物医药ETF

鹏华上证科创板生物医药ETF

<p>Coloplast A/S 报告第二季度亏损 9.71 亿丹麦克朗，较去年 9.12 亿克朗的利润下降，主要由于与 Kerecis 相关的 30.3 亿克朗的减值损失。尽管如此，收入仍增长 2%，达到 70.8 亿克朗，且有机增长为 6%。该公司重申了 2026 财年的展望，预计收入增长 3%，调整后的 EBIT 增长约 5%。将支付每股 5.00 克朗的半年期中期股息</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Coloplast A/S (COLO-B.CO), a medical devices manufacturer, reported Tuesday a loss in its second quarter, compared to prior year's profit, mainly hurt by a hefty impairment loss related to Kerecis, despite higher revenues. Further, the firm reaffirmed fiscal 2026 outlook.</p>
<div class="lb-trans"><p>医疗设备制造商 Coloplast A/S (COLO-B.CO) 周二报告其第二季度亏损，相比于去年同期的盈利，主要受到与 Kerecis 相关的大额减值损失的影响，尽管收入有所增长。此外，该公司重申了 2026 财年的展望。</p>
</div><p>In Copenhagen, the shares were gaining around 0.37 percent, trading at 402.00 Danish kroner.</p>
<div class="lb-trans"><p>在哥本哈根，股价上涨约 0.37%，交易价格为 402.00 丹麦克朗。</p>
</div><p>In the second quarter, the company recorded net loss of 971 million Danish kroner, compared to last year's profit of 912 million kroner. Loss per share was 4.31 kroner, compared to profit of 4.05 kroner a year ago.</p>
<div class="lb-trans"><p>在第二季度，公司录得净亏损 9.71 亿丹麦克朗，而去年同期的盈利为 9.12 亿丹麦克朗。每股亏损为 4.31 丹麦克朗，而去年同期的盈利为 4.05 丹麦克朗。</p>
</div><p>The latest results were mainly hurt by a special impairment loss of 3.03 billion kroner related to Kerecis as a result of the slower market recovery now anticipated in the skin substitutes out-patient setting.</p>
<div class="lb-trans"><p>最新的业绩主要受到与 Kerecis 相关的 30.3 亿丹麦克朗的特殊减值损失的影响，因为预计皮肤替代品的市场复苏速度较慢。</p>
</div><p>Adjusted earnings per share were 6.16 kroner, compared to 4.34 kroner a year ago.</p>
<div class="lb-trans"><p>调整后的每股收益为 6.16 丹麦克朗，而去年同期为 4.34 丹麦克朗。</p>
</div><p>Operating profit or EBIT before special items dropped 4 percent from last year to 1.82 billion kroner. Adjusted EBITDA fell 3 percent to 2.17 billion kroner.</p>
<div class="lb-trans"><p>在特殊项目之前的营业利润或 EBIT 较去年下降 4%，至 18.2 亿丹麦克朗。调整后的 EBITDA 下降 3%，至 21.7 亿丹麦克朗。</p>
</div><p>The adjusted EBIT margin was 26 percent, against 27 percent last year.</p>
<div class="lb-trans"><p>调整后的 EBIT 利润率为 26%，而去年为 27%。</p>
</div><p>Coloplast delivered Q2 organic growth of 6 percent and 6 percent EBIT growth1 in constant currencies. Strong quarter in Chronic Care and Interventional Urology, challenging quarter in Wound &amp; Tissue Repair.</p>
<div class="lb-trans"><p>Coloplast 在第二季度实现了 6% 的有机增长和 6% 的 EBIT 增长（以固定汇率计算）。慢性护理和介入性泌尿学表现强劲，而伤口与组织修复的季度表现则面临挑战。</p>
</div><p>Revenue grew 2 percent to 7.08 billion kroner from 6.93 billion kroner last year, despite 4 percent points negative impact from currencies. Organic growth was 6 percent.</p>
<div class="lb-trans"><p>尽管受到货币的 4 个百分点的负面影响，收入仍增长 2%，从去年的 69.3 亿丹麦克朗增至 70.8 亿丹麦克朗。有机增长为 6%。</p>
</div><p>Further, the company said it will pay a half-year interim dividend of 5.00 kroner per share, for a total dividend pay-out of 1.13 billion kroner.</p>
<div class="lb-trans"><p>此外，公司表示将支付每股 5.00 丹麦克朗的半年期中期股息，总股息支付为 11.3 亿丹麦克朗。</p>
</div><p>Looking ahead for fiscal 2026, Coloplast said it continues to project revenue growth at around 3 percent, with 2 percent to 3 percent-points negative impact from currencies, organic revenue growth at 5 percent to 6 percent, and adjusted EBIT growth in constant currencies of around 5 percent.</p>
<div class="lb-trans"><p>展望 2026 财年，Coloplast 表示预计收入增长约为 3%，货币的负面影响为 2% 至 3 个百分点，有机收入增长为 5% 至 6%，调整后的 EBIT 在固定汇率下增长约 5%。</p>
</div><p>The annual results would include special items of around 3.1 billion kroner, reflecting the Kerecis impairment loss.</p>
<div class="lb-trans"><p>年度业绩将包括约 31 亿丹麦克朗的特殊项目，反映 Kerecis 的减值损失。</p>
</div><p>For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.</p>
<div class="lb-trans"><p>有关更多盈利新闻、盈利日历和股票盈利信息，请访问 rttnews.com。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

Coloplast Slips To Loss In Q2 On Hefty Charge, Revenues Rise; Confirms FY26 Outlook

rttnews

BlackRock, Inc.

方正富邦中证医药及医疗器械创新ETF

科创医药ETF工银

医疗业 ETF - SPDR

标普健康医疗设备 ETF - SPDR

医疗器械ETF永赢

美国制药 ETF - iShares

招商中证全指医疗器械ETF

华夏上证科创板生物医药ETF

美国医药设备 ETF - iShares

标普全球医疗股指数 ETF - iShares

医药突破 ETF - ALPS

平安中证医疗创新ETF

医疗业 ETF - Vanguard

华夏中证全指医疗器械ETF

Coloplast A/S Class B

Coloplast 因巨额费用在第二季度转为亏损，但收入有所上升；确认 2026 财年的展望